A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

NCT01678105 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Salivary Gland Cancers
ACC

Interventions

DRUG: Dovitinib

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators

[object Object]